Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.49 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944569 | 0.88 | TGFBR1 (0.54) | TGFBR1GPR52NOS3NOS1NOS2 | |
| SCHEMBL3952724 | 0.88 | TGFBR1 (0.55) | TGFBR1GPR52MAP3K7IRAK4 | |
| SCHEMBL3949333 | 0.83 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL3946294 | 0.82 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL4181719 | 0.81 | TGFBR1 (0.55) | TGFBR1GPR52 | |
| SCHEMBL3954430 | 0.80 | TGFBR1 (0.46) | TGFBR1GPR52 | |
| SCHEMBL4038595 | 0.80 | TGFBR1 (0.49) | TGFBR1GPR52NOS3NOS1NOS2 | |
| SCHEMBL3944990 | 0.80 | TGFBR1 (0.62) | TGFBR1 | |
| SCHEMBL3946514 | 0.80 | TGFBR1 (0.51) | TGFBR1 | |
| SCHEMBL3946284 | 0.80 | TGFBR1 (0.50) | TGFBR1GPR52NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885GPR52 397/4885NOS3 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.